← Back to patent-cliff list
瑞舒伐他汀钙
Tier C — Watch / tradeRosuvastatin Calcium
盐野义制药株式会社
Originator
2002
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：HMGCR
Brand：可定、冠脂妥、Crestor
Indications (approved)：纯合子家族性高胆固醇血症、杂合子家族性高胆固醇血症、高脂蛋白血症Ⅲ型、动脉粥样硬化、II型高脂蛋白血症、高胆固醇血症、血脂障碍
Regional status
US
批准上市
2003-08-12
EU
批准上市
2002-11-06
China
批准上市
2006-12-27
Japan
批准上市
2005-01-19
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Rosuvastatin Calcium?
Approved indications include: 纯合子家族性高胆固醇血症, 杂合子家族性高胆固醇血症, 高脂蛋白血症Ⅲ型, 动脉粥样硬化, II型高脂蛋白血症, 高胆固醇血症, 血脂障碍.
When does the Rosuvastatin Calcium patent expire?
No public expiry year is available for Rosuvastatin Calcium yet; this page updates once verified.
How do I get a quote for Rosuvastatin Calcium intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-25